Revolution Medicines

Revolution Medicines develops therapies for RAS-addicted cancers. Its treatments target cancer cells, offering hope for patients. The company focuses on precision medicine to improve cancer care.

Products and Services

Daraxonrasib (RMC-6236): Targets multiple RAS(ON) variants in cancer cells.

Elironrasib (RMC-6291): Inhibits the G12C variant of RAS proteins.

Zoldonrasib (RMC-9805): Focuses on the G12D variant in cancer treatment.

RMC-5127: Targets the G12V variant of RAS proteins.

RMC-0708: Inhibits the Q61H variant in cancer cells.

RMC-8839: Focuses on the G13C variant of RAS proteins.

Growth and Expansion

In 2020, Revolution Medicines went public on NASDAQ.

Collaborated with Sanofi for SHP2 inhibitors development.

Expanded product line with RAS(ON) inhibitors in recent years.

What Makes Revolution Medicines Special

Revolution Medicines uses a proprietary technology platform to develop RAS(ON) inhibitors. This approach targets active RAS proteins, offering potential advantages over older methods.

Five Things You Need to Know

Market cap of $7.71 billion as of February 2025.

Stock price ranged from $29.17 to $62.40 in 2024.

Beta of 1.37 indicates higher volatility than the market.

185,913,326 shares outstanding as of February 2025.

Public float of approximately $6.5 billion as of June 2024.

Bottom Line

Revolution Medicines focuses on precision oncology, leveraging innovative technology to target RAS-addicted cancers. Its strategic collaborations and product expansions position it as a key player in cancer treatment.